CA2372805A1 - Variantes de l'autotaxine et leurs utilisations dans le traitement des troubles du metabolisme - Google Patents
Variantes de l'autotaxine et leurs utilisations dans le traitement des troubles du metabolisme Download PDFInfo
- Publication number
- CA2372805A1 CA2372805A1 CA002372805A CA2372805A CA2372805A1 CA 2372805 A1 CA2372805 A1 CA 2372805A1 CA 002372805 A CA002372805 A CA 002372805A CA 2372805 A CA2372805 A CA 2372805A CA 2372805 A1 CA2372805 A1 CA 2372805A1
- Authority
- CA
- Canada
- Prior art keywords
- autotaxin
- amino acid
- seq
- leu
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Les altérations de la sensibilité insulinique sont associées au diabète et à des troubles tels que l'obésité et la dyslipidémie. Des niveaux élevés d'acide gras en circulation libre sous forme de triglycérides, qui constituent une facteur de risque important pour l'athérosclérose, viennent compliquer ces troubles. Les troubles du métabolisme tels que l'obésité, la dyslipidémie et le diabète peuvent être traités au moyen de compositions pharmaceutiques renfermant soit des polypeptides d'autotaxine ou des fragments fonctionnels de ces derniers, soit des molécules d'acides nucléiques codant pour lesdits polypeptides ou leurs fragments. Les polypeptides d'autotaxine convenant pour de telles méthodes thérapeutiques renferment par exemples de nouvelles formes d'autotaxine de l'homme et du rat.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30697999A | 1999-05-07 | 1999-05-07 | |
US09/306,979 | 1999-05-07 | ||
PCT/US2000/012402 WO2000068386A1 (fr) | 1999-05-07 | 2000-05-05 | Variantes de l'autotaxine et leurs utilisations dans le traitement des troubles du metabolisme |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2372805A1 true CA2372805A1 (fr) | 2000-11-16 |
Family
ID=23187734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002372805A Abandoned CA2372805A1 (fr) | 1999-05-07 | 2000-05-05 | Variantes de l'autotaxine et leurs utilisations dans le traitement des troubles du metabolisme |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1177298A1 (fr) |
JP (1) | JP2002543789A (fr) |
AU (1) | AU4825000A (fr) |
CA (1) | CA2372805A1 (fr) |
IL (1) | IL146237A0 (fr) |
NZ (1) | NZ515193A (fr) |
WO (1) | WO2000068386A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2002053569A1 (ja) * | 2000-12-28 | 2004-05-13 | 株式会社アズウェル | リゾホスホリパーゼd活性測定方法 |
US20050222070A1 (en) | 2002-05-29 | 2005-10-06 | Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung | Pancreas-specific proteins |
JP2003284574A (ja) * | 2001-10-03 | 2003-10-07 | Pfizer Prod Inc | 核酸分子、ポリペプチド、ならびにアルツハイマー病の診断および処置を含むそれらの使用 |
WO2003031615A1 (fr) * | 2001-10-04 | 2003-04-17 | Apro Life Science Institute, Inc. | Inhibiteur de l'acide lysophosphatidique synthase |
EP1507553A2 (fr) * | 2002-05-29 | 2005-02-23 | DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung | Proteines specifiques du pancreas |
EP1893224B1 (fr) | 2005-06-10 | 2018-05-02 | Thylabisco AB | Utilisation d'une membrane de cellule vegetale pour le traitement de l'obesite |
CN101523213B (zh) * | 2006-08-03 | 2017-03-08 | 国立大学法人东京大学 | 天然形式人自分泌运动因子特异的抗体、其筛选方法、以及通过测定自分泌运动因子而检测恶性淋巴瘤的方法和检测试剂 |
JP5864918B2 (ja) * | 2011-07-06 | 2016-02-17 | 国立大学法人東北大学 | オートタキシンアイソフォーム特異的抗体および検出方法 |
EP2825199A4 (fr) * | 2012-03-15 | 2016-01-27 | Janssen Biotech Inc | Anticorps dirigés contre l'autotaxine humaine et procédés d'utilisation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5731167A (en) * | 1992-01-17 | 1998-03-24 | The United States Of America As Represented By The Department Of Health And Human Services | Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy |
-
2000
- 2000-05-05 WO PCT/US2000/012402 patent/WO2000068386A1/fr not_active Application Discontinuation
- 2000-05-05 CA CA002372805A patent/CA2372805A1/fr not_active Abandoned
- 2000-05-05 NZ NZ515193A patent/NZ515193A/en unknown
- 2000-05-05 EP EP00930429A patent/EP1177298A1/fr not_active Withdrawn
- 2000-05-05 IL IL14623700A patent/IL146237A0/xx unknown
- 2000-05-05 AU AU48250/00A patent/AU4825000A/en not_active Abandoned
- 2000-05-05 JP JP2000616352A patent/JP2002543789A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU4825000A (en) | 2000-11-21 |
JP2002543789A (ja) | 2002-12-24 |
WO2000068386A1 (fr) | 2000-11-16 |
IL146237A0 (en) | 2002-07-25 |
NZ515193A (en) | 2003-05-30 |
EP1177298A1 (fr) | 2002-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7517958B2 (en) | Interleukin-17 receptor homologue | |
CA2378519C (fr) | Recepteur de cytokine humaine | |
US20080213831A1 (en) | Human cytokine receptor | |
CA2372805A1 (fr) | Variantes de l'autotaxine et leurs utilisations dans le traitement des troubles du metabolisme | |
US20020156259A1 (en) | Human adenosine deaminase | |
US20020146763A1 (en) | Murine cytokine receptor | |
WO2001044281A2 (fr) | Recepteur humain de type secretine | |
US20030166156A1 (en) | Zsig67: a member of the human secretin-glucagon-VIP hormone family | |
US20030092117A1 (en) | Zalpha13: a human secreted protein | |
US20020151492A1 (en) | Testis specific protein | |
US20020095022A1 (en) | Human secretin-like receptor | |
EP1171600A2 (fr) | Zalpha13: proteine humaine secretee | |
WO2000059934A2 (fr) | Proteine specifique des testicules | |
CA2358930A1 (fr) | Zsig67: membre de la famille des hormones humaines secretin-glucagon-vip |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |